#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Acrylamide , a thermal processing contaminant with a low molecular weight , which is soluble in water , is formed when carbohydrate-rich foods are subjected to temperatures above 120 °C in low-moisture conditions , such as frying , roasting or baking .
2-1	16-26	Acrylamide	substance	new	coref	3-12
2-2	27-28	,	_	_	_	_
2-3	29-30	a	abstract[4]	new[4]	coref	8-17[94_4]
2-4	31-38	thermal	abstract[4]	new[4]	_	_
2-5	39-49	processing	abstract|abstract[4]	new|new[4]	_	_
2-6	50-61	contaminant	abstract[4]	new[4]	_	_
2-7	62-66	with	abstract[4]	new[4]	_	_
2-8	67-68	a	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-9	69-72	low	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-10	73-82	molecular	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-11	83-89	weight	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-12	90-91	,	_	_	_	_
2-13	92-97	which	_	_	_	_
2-14	98-100	is	_	_	_	_
2-15	101-108	soluble	_	_	_	_
2-16	109-111	in	_	_	_	_
2-17	112-117	water	substance	new	_	_
2-18	118-119	,	_	_	_	_
2-19	120-122	is	_	_	_	_
2-20	123-129	formed	_	_	_	_
2-21	130-134	when	_	_	_	_
2-22	135-152	carbohydrate-rich	substance[7]	new[7]	coref	3-31[28_7]
2-23	153-158	foods	substance[7]	new[7]	_	_
2-24	159-162	are	_	_	_	_
2-25	163-172	subjected	_	_	_	_
2-26	173-175	to	_	_	_	_
2-27	176-188	temperatures	abstract	new	_	_
2-28	189-194	above	abstract[9]	new[9]	_	_
2-29	195-198	120	abstract[9]	new[9]	_	_
2-30	199-201	°C	abstract[9]	new[9]	_	_
2-31	202-204	in	abstract[9]	new[9]	_	_
2-32	205-217	low-moisture	abstract[9]|abstract[10]	new[9]|new[10]	coref	17-35[194_10]
2-33	218-228	conditions	abstract[9]|abstract[10]	new[9]|new[10]	_	_
2-34	229-230	,	abstract[9]|abstract[10]	new[9]|new[10]	_	_
2-35	231-235	such	abstract[9]|abstract[10]	new[9]|new[10]	_	_
2-36	236-238	as	abstract[9]|abstract[10]	new[9]|new[10]	_	_
2-37	239-245	frying	abstract[9]|abstract[10]|event	new[9]|new[10]|new	_	_
2-38	246-247	,	abstract[9]|abstract[10]	new[9]|new[10]	_	_
2-39	248-256	roasting	abstract[9]|abstract[10]|abstract	new[9]|new[10]|new	_	_
2-40	257-259	or	abstract[9]|abstract[10]	new[9]|new[10]	_	_
2-41	260-266	baking	abstract[9]|abstract[10]|person	new[9]|new[10]|new	_	_
2-42	267-268	.	_	_	_	_

#Text=Several studies consider Maillard reactions to be the main pathway for acrylamide , 5 hydroxymethylfurfural , methylglyoxal – lysine dimers , Nε – carboxymethyl – lysine and pyrraline formation in processed foods , particularly reactions between the carbonyl group of reducing sugars and amino acids .
3-1	269-276	Several	abstract[14]	new[14]	coref	12-17[141_14]
3-2	277-284	studies	abstract[14]	new[14]	_	_
3-3	285-293	consider	_	_	_	_
3-4	294-302	Maillard	person|event[16]	new|new[16]	appos	3-34[29_16]
3-5	303-312	reactions	event[16]	new[16]	_	_
3-6	313-315	to	_	_	_	_
3-7	316-318	be	_	_	_	_
3-8	319-322	the	place[17]	new[17]	_	_
3-9	323-327	main	place[17]	new[17]	_	_
3-10	328-335	pathway	place[17]	new[17]	_	_
3-11	336-339	for	place[17]	new[17]	_	_
3-12	340-350	acrylamide	place[17]|substance	new[17]|giv	coref	4-8
3-13	351-352	,	place[17]	new[17]	_	_
3-14	353-354	5	place[17]|substance[19]	new[17]|new[19]	_	_
3-15	355-376	hydroxymethylfurfural	place[17]|substance[19]	new[17]|new[19]	_	_
3-16	377-378	,	place[17]	new[17]	_	_
3-17	379-392	methylglyoxal	place[17]|substance	new[17]|new	_	_
3-18	393-394	–	place[17]	new[17]	_	_
3-19	395-401	lysine	place[17]|abstract|substance[22]	new[17]|new|new[22]	coref	3-26
3-20	402-408	dimers	place[17]|substance[22]	new[17]|new[22]	_	_
3-21	409-410	,	place[17]	new[17]	_	_
3-22	411-413	Nε	place[17]|substance[23]	new[17]|new[23]	_	_
3-23	414-415	–	place[17]|substance[23]	new[17]|new[23]	_	_
3-24	416-429	carboxymethyl	place[17]|substance[23]|substance	new[17]|new[23]|new	_	_
3-25	430-431	–	_	_	_	_
3-26	432-438	lysine	substance|abstract[27]	giv|new[27]	coref	9-18[100_27]
3-27	439-442	and	abstract[27]	new[27]	_	_
3-28	443-452	pyrraline	abstract|abstract[27]	new|new[27]	_	_
3-29	453-462	formation	abstract[27]	new[27]	_	_
3-30	463-465	in	abstract[27]	new[27]	_	_
3-31	466-475	processed	abstract[27]|substance[28]	new[27]|giv[28]	_	_
3-32	476-481	foods	abstract[27]|substance[28]	new[27]|giv[28]	_	_
3-33	482-483	,	_	_	_	_
3-34	484-496	particularly	event[29]	giv[29]	_	_
3-35	497-506	reactions	event[29]	giv[29]	_	_
3-36	507-514	between	event[29]	giv[29]	_	_
3-37	515-518	the	event[29]|person[31]	giv[29]|new[31]	_	_
3-38	519-527	carbonyl	event[29]|abstract|person[31]	giv[29]|new|new[31]	_	_
3-39	528-533	group	event[29]|person[31]	giv[29]|new[31]	_	_
3-40	534-536	of	_	_	_	_
3-41	537-545	reducing	_	_	_	_
3-42	546-552	sugars	substance	new	_	_
3-43	553-556	and	_	_	_	_
3-44	557-562	amino	substance[33]	new[33]	_	_
3-45	563-568	acids	substance[33]	new[33]	_	_
3-46	569-570	.	_	_	_	_

#Text=Initial reports showed relatively high concentrations of acrylamide in high-carbohydrate foodstuffs , such as crispy bread , breakfast cereals , pastries , coffee , French fries and crisps .
4-1	571-578	Initial	abstract[34]	new[34]	_	_
4-2	579-586	reports	abstract[34]	new[34]	_	_
4-3	587-593	showed	_	_	_	_
4-4	594-604	relatively	animal[35]	new[35]	_	_
4-5	605-609	high	animal[35]	new[35]	_	_
4-6	610-624	concentrations	animal[35]	new[35]	_	_
4-7	625-627	of	animal[35]	new[35]	_	_
4-8	628-638	acrylamide	animal[35]|substance	new[35]|giv	coref	5-8
4-9	639-641	in	animal[35]	new[35]	_	_
4-10	642-659	high-carbohydrate	animal[35]|substance[37]	new[35]|new[37]	_	_
4-11	660-670	foodstuffs	animal[35]|substance[37]	new[35]|new[37]	_	_
4-12	671-672	,	animal[35]|substance[37]	new[35]|new[37]	_	_
4-13	673-677	such	animal[35]|substance[37]	new[35]|new[37]	_	_
4-14	678-680	as	animal[35]|substance[37]	new[35]|new[37]	_	_
4-15	681-687	crispy	animal[35]|substance[37]|object[38]	new[35]|new[37]|new[38]	_	_
4-16	688-693	bread	animal[35]|substance[37]|object[38]	new[35]|new[37]|new[38]	_	_
4-17	694-695	,	animal[35]|substance[37]	new[35]|new[37]	_	_
4-18	696-705	breakfast	animal[35]|substance[37]|substance[39]	new[35]|new[37]|new[39]	_	_
4-19	706-713	cereals	animal[35]|substance[37]|substance[39]	new[35]|new[37]|new[39]	_	_
4-20	714-715	,	animal[35]|substance[37]	new[35]|new[37]	_	_
4-21	716-724	pastries	animal[35]|substance[37]|object	new[35]|new[37]|new	_	_
4-22	725-726	,	animal[35]|substance[37]	new[35]|new[37]	_	_
4-23	727-733	coffee	animal[35]|substance[37]|substance	new[35]|new[37]|new	_	_
4-24	734-735	,	animal[35]|substance[37]	new[35]|new[37]	_	_
4-25	736-742	French	animal[35]|substance[37]|object[42]	new[35]|new[37]|new[42]	_	_
4-26	743-748	fries	animal[35]|substance[37]|object[42]	new[35]|new[37]|new[42]	_	_
4-27	749-752	and	animal[35]|substance[37]	new[35]|new[37]	_	_
4-28	753-759	crisps	animal[35]|substance[37]|object	new[35]|new[37]|new	coref	7-28
4-29	760-761	.	_	_	_	_

#Text=In general , potato products present higher acrylamide contents ( 250 – 4000 µg kg−1 ) compared to other food products , because of the higher concentration of asparagine in potato tubers .
5-1	762-764	In	_	_	_	_
5-2	765-772	general	abstract	new	_	_
5-3	773-774	,	_	_	_	_
5-4	775-781	potato	object|object[46]	new|new[46]	coref|coref	5-19[53_46]|5-31
5-5	782-790	products	object[46]	new[46]	_	_
5-6	791-798	present	_	_	_	_
5-7	799-805	higher	quantity[48]	new[48]	appos	5-11[49_48]
5-8	806-816	acrylamide	substance|quantity[48]	giv|new[48]	coref	6-1
5-9	817-825	contents	quantity[48]	new[48]	_	_
5-10	826-827	(	_	_	_	_
5-11	828-831	250	quantity[49]	giv[49]	_	_
5-12	832-833	–	quantity[49]	giv[49]	_	_
5-13	834-838	4000	quantity[49]|quantity	giv[49]|new	_	_
5-14	839-841	µg	quantity[49]|abstract|quantity[52]	giv[49]|new|new[52]	_	_
5-15	842-846	kg−1	quantity[49]|quantity[52]	giv[49]|new[52]	_	_
5-16	847-848	)	_	_	_	_
5-17	849-857	compared	_	_	_	_
5-18	858-860	to	_	_	_	_
5-19	861-866	other	object[53]	giv[53]	_	_
5-20	867-871	food	object[53]	giv[53]	_	_
5-21	872-880	products	object[53]	giv[53]	_	_
5-22	881-882	,	_	_	_	_
5-23	883-890	because	_	_	_	_
5-24	891-893	of	_	_	_	_
5-25	894-897	the	abstract[54]	new[54]	_	_
5-26	898-904	higher	abstract[54]	new[54]	_	_
5-27	905-918	concentration	abstract[54]	new[54]	_	_
5-28	919-921	of	abstract[54]	new[54]	_	_
5-29	922-932	asparagine	abstract[54]|substance[55]	new[54]|new[55]	_	_
5-30	933-935	in	abstract[54]|substance[55]	new[54]|new[55]	_	_
5-31	936-942	potato	abstract[54]|substance[55]|object|plant[57]	new[54]|new[55]|giv|new[57]	coref	9-61
5-32	943-949	tubers	abstract[54]|substance[55]|plant[57]	new[54]|new[55]|new[57]	_	_
5-33	950-951	.	_	_	_	_

#Text=Acrylamide has been classified by the Agency for Research on Cancer as “ probably carcinogenic to humans ” ( Group 2A ) and , in the latest report from the European Food Safety Authority Expert Panel on Contaminants in the Food Chain ( CONTAM , 2015 ) , the margins of exposure for acrylamide lead to concerns regarding their neoplastic effects , based on animal evidence .
6-1	952-962	Acrylamide	substance	giv	coref	6-54
6-2	963-966	has	_	_	_	_
6-3	967-971	been	_	_	_	_
6-4	972-982	classified	_	_	_	_
6-5	983-985	by	_	_	_	_
6-6	986-989	the	organization[59]	new[59]	_	_
6-7	990-996	Agency	organization[59]	new[59]	_	_
6-8	997-1000	for	organization[59]	new[59]	_	_
6-9	1001-1009	Research	organization[59]|abstract[60]	new[59]|new[60]	_	_
6-10	1010-1012	on	organization[59]|abstract[60]	new[59]|new[60]	_	_
6-11	1013-1019	Cancer	organization[59]|abstract[60]|abstract	new[59]|new[60]|new	_	_
6-12	1020-1022	as	_	_	_	_
6-13	1023-1024	“	_	_	_	_
6-14	1025-1033	probably	_	_	_	_
6-15	1034-1046	carcinogenic	_	_	_	_
6-16	1047-1049	to	_	_	_	_
6-17	1050-1056	humans	person	new	coref	13-4
6-18	1057-1058	”	_	_	_	_
6-19	1059-1060	(	_	_	_	_
6-20	1061-1066	Group	_	_	_	_
6-21	1067-1069	2A	_	_	_	_
6-22	1070-1071	)	_	_	_	_
6-23	1072-1075	and	_	_	_	_
6-24	1076-1077	,	_	_	_	_
6-25	1078-1080	in	_	_	_	_
6-26	1081-1084	the	abstract[63]	new[63]	_	_
6-27	1085-1091	latest	abstract[63]	new[63]	_	_
6-28	1092-1098	report	abstract[63]	new[63]	_	_
6-29	1099-1103	from	abstract[63]	new[63]	_	_
6-30	1104-1107	the	abstract[63]|person[67]	new[63]|new[67]	_	_
6-31	1108-1116	European	abstract[63]|substance[64]|person[67]	new[63]|new[64]|new[67]	coref	6-41[0_64]
6-32	1117-1121	Food	abstract[63]|substance[64]|person[67]	new[63]|new[64]|new[67]	_	_
6-33	1122-1128	Safety	abstract[63]|abstract|person[67]	new[63]|new|new[67]	_	_
6-34	1129-1138	Authority	abstract[63]|organization|person[67]	new[63]|new|new[67]	_	_
6-35	1139-1145	Expert	abstract[63]|person[67]	new[63]|new[67]	_	_
6-36	1146-1151	Panel	abstract[63]|person[67]	new[63]|new[67]	_	_
6-37	1152-1154	on	abstract[63]|person[67]	new[63]|new[67]	_	_
6-38	1155-1167	Contaminants	abstract[63]|person[67]|person	new[63]|new[67]|new	ana	6-59
6-39	1168-1170	in	abstract[63]|person[67]	new[63]|new[67]	_	_
6-40	1171-1174	the	abstract[63]|person[67]|abstract[70]	new[63]|new[67]|new[70]	_	_
6-41	1175-1179	Food	abstract[63]|person[67]|substance|abstract[70]	new[63]|new[67]|giv|new[70]	coref	7-18
6-42	1180-1185	Chain	abstract[63]|person[67]|abstract[70]	new[63]|new[67]|new[70]	_	_
6-43	1186-1187	(	_	_	_	_
6-44	1188-1194	CONTAM	object[71]	new[71]	_	_
6-45	1195-1196	,	object[71]	new[71]	_	_
6-46	1197-1201	2015	object[71]	new[71]	_	_
6-47	1202-1203	)	_	_	_	_
6-48	1204-1205	,	_	_	_	_
6-49	1206-1209	the	abstract[72]	new[72]	_	_
6-50	1210-1217	margins	abstract[72]	new[72]	_	_
6-51	1218-1220	of	abstract[72]	new[72]	_	_
6-52	1221-1229	exposure	abstract[72]|abstract	new[72]|new	_	_
6-53	1230-1233	for	abstract[72]	new[72]	_	_
6-54	1234-1244	acrylamide	abstract[72]|substance|abstract[75]	new[72]|giv|new[75]	coref	7-16[84_0]
6-55	1245-1249	lead	abstract[72]|abstract[75]	new[72]|new[75]	_	_
6-56	1250-1252	to	abstract[72]|abstract[75]	new[72]|new[75]	_	_
6-57	1253-1261	concerns	abstract[72]|abstract[75]|abstract	new[72]|new[75]|new	_	_
6-58	1262-1271	regarding	_	_	_	_
6-59	1272-1277	their	person|abstract[78]	giv|new[78]	coref	16-11
6-60	1278-1288	neoplastic	abstract[78]	new[78]	_	_
6-61	1289-1296	effects	abstract[78]	new[78]	_	_
6-62	1297-1298	,	_	_	_	_
6-63	1299-1304	based	_	_	_	_
6-64	1305-1307	on	_	_	_	_
6-65	1308-1314	animal	animal|abstract[80]	new|new[80]	_	_
6-66	1315-1323	evidence	abstract[80]	new[80]	_	_
6-67	1324-1325	.	_	_	_	_

#Text=Therefore , the European Commission recently established “ indicative ” levels for the presence of acrylamide in food , suggesting a limit of 750 µg kg−1 for crisps .
7-1	1326-1335	Therefore	_	_	_	_
7-2	1336-1337	,	_	_	_	_
7-3	1338-1341	the	organization[81]	new[81]	_	_
7-4	1342-1350	European	organization[81]	new[81]	_	_
7-5	1351-1361	Commission	organization[81]	new[81]	_	_
7-6	1362-1370	recently	_	_	_	_
7-7	1371-1382	established	_	_	_	_
7-8	1383-1384	“	abstract[82]	new[82]	coref	10-16[119_82]
7-9	1385-1395	indicative	abstract[82]	new[82]	_	_
7-10	1396-1397	”	abstract[82]	new[82]	_	_
7-11	1398-1404	levels	abstract[82]	new[82]	_	_
7-12	1405-1408	for	abstract[82]	new[82]	_	_
7-13	1409-1412	the	abstract[82]|abstract[83]	new[82]|new[83]	_	_
7-14	1413-1421	presence	abstract[82]|abstract[83]	new[82]|new[83]	_	_
7-15	1422-1424	of	abstract[82]|abstract[83]	new[82]|new[83]	_	_
7-16	1425-1435	acrylamide	abstract[82]|abstract[83]|substance[84]	new[82]|new[83]|giv[84]	coref	9-18[0_84]
7-17	1436-1438	in	abstract[82]|abstract[83]|substance[84]	new[82]|new[83]|giv[84]	_	_
7-18	1439-1443	food	abstract[82]|abstract[83]|substance[84]|substance	new[82]|new[83]|giv[84]|giv	coref	8-10
7-19	1444-1445	,	_	_	_	_
7-20	1446-1456	suggesting	_	_	_	_
7-21	1457-1458	a	abstract[86]	new[86]	_	_
7-22	1459-1464	limit	abstract[86]	new[86]	_	_
7-23	1465-1467	of	abstract[86]	new[86]	_	_
7-24	1468-1471	750	abstract[86]|quantity[87]	new[86]|new[87]	_	_
7-25	1472-1474	µg	abstract[86]|quantity[87]	new[86]|new[87]	_	_
7-26	1475-1479	kg−1	abstract[86]|quantity[87]	new[86]|new[87]	_	_
7-27	1480-1483	for	abstract[86]|quantity[87]	new[86]|new[87]	_	_
7-28	1484-1490	crisps	abstract[86]|quantity[87]|substance	new[86]|new[87]|giv	coref	12-28
7-29	1491-1492	.	_	_	_	_

#Text=Previously , the European Union and FDA had encouraged food industries to reduce the presence of this contaminant .
8-1	1493-1503	Previously	_	_	_	_
8-2	1504-1505	,	_	_	_	_
8-3	1506-1509	the	organization[89]	new[89]	_	_
8-4	1510-1518	European	organization[89]	new[89]	_	_
8-5	1519-1524	Union	organization[89]	new[89]	_	_
8-6	1525-1528	and	_	_	_	_
8-7	1529-1532	FDA	organization	new	_	_
8-8	1533-1536	had	_	_	_	_
8-9	1537-1547	encouraged	_	_	_	_
8-10	1548-1552	food	substance|abstract[92]	giv|new[92]	coref|coref	9-7|10-7[115_92]
8-11	1553-1563	industries	abstract[92]	new[92]	_	_
8-12	1564-1566	to	_	_	_	_
8-13	1567-1573	reduce	_	_	_	_
8-14	1574-1577	the	abstract[93]	new[93]	_	_
8-15	1578-1586	presence	abstract[93]	new[93]	_	_
8-16	1587-1589	of	abstract[93]	new[93]	_	_
8-17	1590-1594	this	abstract[93]|abstract[94]	new[93]|giv[94]	_	_
8-18	1595-1606	contaminant	abstract[93]|abstract[94]	new[93]|giv[94]	_	_
8-19	1607-1608	.	_	_	_	_

#Text=In response to this , the food industry has been forced to apply different strategies to reduce acrylamide formation , applying processing modifications according to recommendations published by the European Food and Drink Federation in the document “ Acrylamide Toolbox ” , which includes the following variables : temperature and time during frying , blanching treatment , and thickness of potato slices .
9-1	1609-1611	In	_	_	_	_
9-2	1612-1620	response	abstract[95]	new[95]	_	_
9-3	1621-1623	to	abstract[95]	new[95]	_	_
9-4	1624-1628	this	abstract[95]	new[95]	_	_
9-5	1629-1630	,	_	_	_	_
9-6	1631-1634	the	organization[97]	new[97]	_	_
9-7	1635-1639	food	substance|organization[97]	giv|new[97]	coref	9-30[103_0]
9-8	1640-1648	industry	organization[97]	new[97]	_	_
9-9	1649-1652	has	_	_	_	_
9-10	1653-1657	been	_	_	_	_
9-11	1658-1664	forced	_	_	_	_
9-12	1665-1667	to	_	_	_	_
9-13	1668-1673	apply	_	_	_	_
9-14	1674-1683	different	abstract[98]	new[98]	coref	18-5[198_98]
9-15	1684-1694	strategies	abstract[98]	new[98]	_	_
9-16	1695-1697	to	_	_	_	_
9-17	1698-1704	reduce	_	_	_	_
9-18	1705-1715	acrylamide	substance|abstract[100]	giv|giv[100]	coref	9-39
9-19	1716-1725	formation	abstract[100]	giv[100]	_	_
9-20	1726-1727	,	_	_	_	_
9-21	1728-1736	applying	_	_	_	_
9-22	1737-1747	processing	_	_	_	_
9-23	1748-1761	modifications	abstract[101]	new[101]	_	_
9-24	1762-1771	according	abstract[101]	new[101]	_	_
9-25	1772-1774	to	abstract[101]	new[101]	_	_
9-26	1775-1790	recommendations	abstract[101]|abstract	new[101]|new	_	_
9-27	1791-1800	published	_	_	_	_
9-28	1801-1803	by	_	_	_	_
9-29	1804-1807	the	organization[105]	new[105]	_	_
9-30	1808-1816	European	object[103]|organization[105]	giv[103]|new[105]	coref	10-8[0_103]
9-31	1817-1821	Food	object[103]|organization[105]	giv[103]|new[105]	_	_
9-32	1822-1825	and	organization[105]	new[105]	_	_
9-33	1826-1831	Drink	person|organization[105]	new|new[105]	_	_
9-34	1832-1842	Federation	organization[105]	new[105]	_	_
9-35	1843-1845	in	organization[105]	new[105]	_	_
9-36	1846-1849	the	organization[105]|object[106]	new[105]|new[106]	appos	9-39[108_106]
9-37	1850-1858	document	organization[105]|object[106]	new[105]|new[106]	_	_
9-38	1859-1860	“	_	_	_	_
9-39	1861-1871	Acrylamide	substance|object[108]	giv|giv[108]	coref|ana	10-17|11-2[0_108]
9-40	1872-1879	Toolbox	object[108]	giv[108]	_	_
9-41	1880-1881	”	_	_	_	_
9-42	1882-1883	,	_	_	_	_
9-43	1884-1889	which	_	_	_	_
9-44	1890-1898	includes	_	_	_	_
9-45	1899-1902	the	abstract[109]	new[109]	appos	9-49[110_109]
9-46	1903-1912	following	abstract[109]	new[109]	_	_
9-47	1913-1922	variables	abstract[109]	new[109]	_	_
9-48	1923-1924	:	_	_	_	_
9-49	1925-1936	temperature	abstract[110]	giv[110]	coref	11-13[0_110]
9-50	1937-1940	and	abstract[110]	giv[110]	_	_
9-51	1941-1945	time	abstract[110]	giv[110]	_	_
9-52	1946-1952	during	abstract[110]	giv[110]	_	_
9-53	1953-1959	frying	abstract[110]	giv[110]	_	_
9-54	1960-1961	,	abstract[110]	giv[110]	_	_
9-55	1962-1971	blanching	abstract[110]	giv[110]	_	_
9-56	1972-1981	treatment	abstract[110]	giv[110]	_	_
9-57	1982-1983	,	abstract[110]	giv[110]	_	_
9-58	1984-1987	and	abstract[110]	giv[110]	_	_
9-59	1988-1997	thickness	abstract[110]	giv[110]	_	_
9-60	1998-2000	of	abstract[110]	giv[110]	_	_
9-61	2001-2007	potato	abstract[110]|object|object[112]	giv[110]|giv|new[112]	coref	10-13
9-62	2008-2014	slices	abstract[110]|object[112]	giv[110]|new[112]	_	_
9-63	2015-2016	.	_	_	_	_

#Text=However , the main challenge for the food industries is in producing potato chips with low acrylamide levels without affecting their sensory properties .
10-1	2017-2024	However	_	_	_	_
10-2	2025-2026	,	_	_	_	_
10-3	2027-2030	the	abstract[113]	new[113]	_	_
10-4	2031-2035	main	abstract[113]	new[113]	_	_
10-5	2036-2045	challenge	abstract[113]	new[113]	_	_
10-6	2046-2049	for	abstract[113]	new[113]	_	_
10-7	2050-2053	the	abstract[113]|abstract[115]	new[113]|giv[115]	_	_
10-8	2054-2058	food	abstract[113]|object|abstract[115]	new[113]|giv|giv[115]	coref	12-10
10-9	2059-2069	industries	abstract[113]|abstract[115]	new[113]|giv[115]	_	_
10-10	2070-2072	is	_	_	_	_
10-11	2073-2075	in	_	_	_	_
10-12	2076-2085	producing	_	_	_	_
10-13	2086-2092	potato	object|object[117]	giv|new[117]	ana|coref	10-21[0_117]|12-1
10-14	2093-2098	chips	object[117]	new[117]	_	_
10-15	2099-2103	with	_	_	_	_
10-16	2104-2107	low	abstract[119]	giv[119]	ana	11-25[0_119]
10-17	2108-2118	acrylamide	substance|abstract[119]	giv|giv[119]	coref	11-16
10-18	2119-2125	levels	abstract[119]	giv[119]	_	_
10-19	2126-2133	without	_	_	_	_
10-20	2134-2143	affecting	_	_	_	_
10-21	2144-2149	their	object|abstract[121]	giv|new[121]	coref|coref	12-1[137_0]|18-21[204_121]
10-22	2150-2157	sensory	abstract[121]	new[121]	_	_
10-23	2158-2168	properties	abstract[121]	new[121]	_	_
10-24	2169-2170	.	_	_	_	_

#Text=Although it is important to evaluate the effect of pre-treatments on the frying process on acrylamide mitigation , it is also necessary to determine their influence on its bioavailability .
11-1	2171-2179	Although	_	_	_	_
11-2	2180-2182	it	object	giv	_	_
11-3	2183-2185	is	_	_	_	_
11-4	2186-2195	important	_	_	_	_
11-5	2196-2198	to	person[123]	new[123]	_	_
11-6	2199-2207	evaluate	person[123]	new[123]	_	_
11-7	2208-2211	the	person[123]|abstract[124]	new[123]|new[124]	_	_
11-8	2212-2218	effect	person[123]|abstract[124]	new[123]|new[124]	_	_
11-9	2219-2221	of	person[123]|abstract[124]	new[123]|new[124]	_	_
11-10	2222-2236	pre-treatments	person[123]|abstract[124]|substance	new[123]|new[124]|new	_	_
11-11	2237-2239	on	person[123]|abstract[124]	new[123]|new[124]	_	_
11-12	2240-2243	the	person[123]|abstract[124]|event[127]	new[123]|new[124]|new[127]	coref	12-32[146_127]
11-13	2244-2250	frying	person[123]|abstract[124]|abstract|event[127]	new[123]|new[124]|giv|new[127]	_	_
11-14	2251-2258	process	person[123]|abstract[124]|event[127]	new[123]|new[124]|new[127]	_	_
11-15	2259-2261	on	person[123]|abstract[124]|event[127]	new[123]|new[124]|new[127]	_	_
11-16	2262-2272	acrylamide	person[123]|abstract[124]|event[127]|substance|substance[129]	new[123]|new[124]|new[127]|giv|new[129]	coref|coref	12-26|18-7[0_129]
11-17	2273-2283	mitigation	person[123]|abstract[124]|event[127]|substance[129]	new[123]|new[124]|new[127]|new[129]	_	_
11-18	2284-2285	,	_	_	_	_
11-19	2286-2288	it	abstract	new	cata	11-19[0_131]
11-20	2289-2291	is	_	_	_	_
11-21	2292-2296	also	_	_	_	_
11-22	2297-2306	necessary	_	_	_	_
11-23	2307-2309	to	abstract[131]	new[131]	ana	11-28[0_131]
11-24	2310-2319	determine	abstract[131]	new[131]	_	_
11-25	2320-2325	their	abstract[131]|abstract|abstract[133]	new[131]|giv|new[133]	coref	18-18[203_133]
11-26	2326-2335	influence	abstract[131]|abstract[133]	new[131]|new[133]	_	_
11-27	2336-2338	on	_	_	_	_
11-28	2339-2342	its	abstract|abstract[135]	giv|new[135]	coref	12-23[142_135]
11-29	2343-2358	bioavailability	abstract[135]	new[135]	_	_
11-30	2359-2360	.	_	_	_	_

#Text=Potato chips are an important part of the snack food market in many countries , and few studies have been published about the bioavailability of acrylamide after crisps have been through the digestion process .
12-1	2361-2367	Potato	object|substance[137]	giv|giv[137]	_	_
12-2	2368-2373	chips	substance[137]	giv[137]	_	_
12-3	2374-2377	are	_	_	_	_
12-4	2378-2380	an	_	_	_	_
12-5	2381-2390	important	_	_	_	_
12-6	2391-2395	part	_	_	_	_
12-7	2396-2398	of	_	_	_	_
12-8	2399-2402	the	abstract[139]	new[139]	_	_
12-9	2403-2408	snack	abstract[139]	new[139]	_	_
12-10	2409-2413	food	object|abstract[139]	giv|new[139]	coref	13-8
12-11	2414-2420	market	abstract[139]	new[139]	_	_
12-12	2421-2423	in	_	_	_	_
12-13	2424-2428	many	place[140]	new[140]	_	_
12-14	2429-2438	countries	place[140]	new[140]	_	_
12-15	2439-2440	,	_	_	_	_
12-16	2441-2444	and	_	_	_	_
12-17	2445-2448	few	abstract[141]	giv[141]	_	_
12-18	2449-2456	studies	abstract[141]	giv[141]	_	_
12-19	2457-2461	have	_	_	_	_
12-20	2462-2466	been	_	_	_	_
12-21	2467-2476	published	_	_	_	_
12-22	2477-2482	about	_	_	_	_
12-23	2483-2486	the	abstract[142]	giv[142]	_	_
12-24	2487-2502	bioavailability	abstract[142]	giv[142]	_	_
12-25	2503-2505	of	abstract[142]	giv[142]	_	_
12-26	2506-2516	acrylamide	abstract[142]|substance	giv[142]|giv	coref	13-1
12-27	2517-2522	after	_	_	_	_
12-28	2523-2529	crisps	object	giv	_	_
12-29	2530-2534	have	_	_	_	_
12-30	2535-2539	been	_	_	_	_
12-31	2540-2547	through	_	_	_	_
12-32	2548-2551	the	event[146]	giv[146]	coref	14-30[166_146]
12-33	2552-2561	digestion	abstract|event[146]	new|giv[146]	coref	14-31
12-34	2562-2569	process	event[146]	giv[146]	_	_
12-35	2570-2571	.	_	_	_	_

#Text=Acrylamide intake in humans occurs mainly via food ingestion , where the total amount of this compound does not necessarily reflect the available amount to the body .
13-1	2572-2582	Acrylamide	substance|event[148]	giv|new[148]	coref	18-6
13-2	2583-2589	intake	event[148]	new[148]	_	_
13-3	2590-2592	in	event[148]	new[148]	_	_
13-4	2593-2599	humans	event[148]|person	new[148]|giv	_	_
13-5	2600-2606	occurs	_	_	_	_
13-6	2607-2613	mainly	_	_	_	_
13-7	2614-2617	via	_	_	_	_
13-8	2618-2622	food	substance|abstract[151]	giv|new[151]	coref	14-6[157_0]
13-9	2623-2632	ingestion	abstract[151]	new[151]	_	_
13-10	2633-2634	,	_	_	_	_
13-11	2635-2640	where	_	_	_	_
13-12	2641-2644	the	quantity[152]	new[152]	_	_
13-13	2645-2650	total	quantity[152]	new[152]	_	_
13-14	2651-2657	amount	quantity[152]	new[152]	_	_
13-15	2658-2660	of	quantity[152]	new[152]	_	_
13-16	2661-2665	this	quantity[152]|substance[153]	new[152]|new[153]	coref	15-13[170_153]
13-17	2666-2674	compound	quantity[152]|substance[153]	new[152]|new[153]	_	_
13-18	2675-2679	does	_	_	_	_
13-19	2680-2683	not	_	_	_	_
13-20	2684-2695	necessarily	_	_	_	_
13-21	2696-2703	reflect	_	_	_	_
13-22	2704-2707	the	quantity[154]	new[154]	ana	14-9[0_154]
13-23	2708-2717	available	quantity[154]	new[154]	_	_
13-24	2718-2724	amount	quantity[154]	new[154]	_	_
13-25	2725-2727	to	quantity[154]	new[154]	_	_
13-26	2728-2731	the	quantity[154]|object[155]	new[154]|new[155]	_	_
13-27	2732-2736	body	quantity[154]|object[155]	new[154]|new[155]	_	_
13-28	2737-2738	.	_	_	_	_

#Text=There are chemical changes in the food when it enters the digestive tract , because of pH variations , and the action of several enzymes in every stage of the digestion process .
14-1	2739-2744	There	_	_	_	_
14-2	2745-2748	are	_	_	_	_
14-3	2749-2757	chemical	abstract[156]	new[156]	_	_
14-4	2758-2765	changes	abstract[156]	new[156]	_	_
14-5	2766-2768	in	abstract[156]	new[156]	_	_
14-6	2769-2772	the	abstract[156]|substance[157]	new[156]|giv[157]	coref	15-25[0_157]
14-7	2773-2777	food	abstract[156]|substance[157]	new[156]|giv[157]	_	_
14-8	2778-2782	when	_	_	_	_
14-9	2783-2785	it	quantity	giv	coref	15-10[169_0]
14-10	2786-2792	enters	_	_	_	_
14-11	2793-2796	the	object[159]	new[159]	coref	15-28[175_159]
14-12	2797-2806	digestive	object[159]	new[159]	_	_
14-13	2807-2812	tract	object[159]	new[159]	_	_
14-14	2813-2814	,	object[159]	new[159]	_	_
14-15	2815-2822	because	object[159]	new[159]	_	_
14-16	2823-2825	of	object[159]	new[159]	_	_
14-17	2826-2828	pH	object[159]|abstract|abstract[161]	new[159]|new|new[161]	_	_
14-18	2829-2839	variations	object[159]|abstract[161]	new[159]|new[161]	_	_
14-19	2840-2841	,	_	_	_	_
14-20	2842-2845	and	_	_	_	_
14-21	2846-2849	the	event[162]	new[162]	_	_
14-22	2850-2856	action	event[162]	new[162]	_	_
14-23	2857-2859	of	event[162]	new[162]	_	_
14-24	2860-2867	several	event[162]|abstract[163]	new[162]|new[163]	_	_
14-25	2868-2875	enzymes	event[162]|abstract[163]	new[162]|new[163]	_	_
14-26	2876-2878	in	event[162]|abstract[163]	new[162]|new[163]	_	_
14-27	2879-2884	every	event[162]|abstract[163]|abstract[164]	new[162]|new[163]|new[164]	_	_
14-28	2885-2890	stage	event[162]|abstract[163]|abstract[164]	new[162]|new[163]|new[164]	_	_
14-29	2891-2893	of	event[162]|abstract[163]|abstract[164]	new[162]|new[163]|new[164]	_	_
14-30	2894-2897	the	event[162]|abstract[163]|abstract[164]|event[166]	new[162]|new[163]|new[164]|giv[166]	_	_
14-31	2898-2907	digestion	event[162]|abstract[163]|abstract[164]|abstract|event[166]	new[162]|new[163]|new[164]|giv|giv[166]	coref	18-31
14-32	2908-2915	process	event[162]|abstract[163]|abstract[164]|event[166]	new[162]|new[163]|new[164]|giv[166]	_	_
14-33	2916-2917	.	_	_	_	_

#Text=In this sense , bioaccessibility is used to evaluate the amount of a chemical compound available for absorption after it is released from the food matrix into the gastrointestinal tract .
15-1	2918-2920	In	_	_	_	_
15-2	2921-2925	this	abstract[167]	new[167]	_	_
15-3	2926-2931	sense	abstract[167]	new[167]	_	_
15-4	2932-2933	,	_	_	_	_
15-5	2934-2950	bioaccessibility	substance	new	coref	16-8[177_0]
15-6	2951-2953	is	_	_	_	_
15-7	2954-2958	used	_	_	_	_
15-8	2959-2961	to	_	_	_	_
15-9	2962-2970	evaluate	_	_	_	_
15-10	2971-2974	the	quantity[169]	giv[169]	_	_
15-11	2975-2981	amount	quantity[169]	giv[169]	_	_
15-12	2982-2984	of	quantity[169]	giv[169]	_	_
15-13	2985-2986	a	quantity[169]|substance[170]	giv[169]|giv[170]	ana	15-20[0_170]
15-14	2987-2995	chemical	quantity[169]|substance[170]	giv[169]|giv[170]	_	_
15-15	2996-3004	compound	quantity[169]|substance[170]	giv[169]|giv[170]	_	_
15-16	3005-3014	available	quantity[169]|substance[170]	giv[169]|giv[170]	_	_
15-17	3015-3018	for	_	_	_	_
15-18	3019-3029	absorption	abstract	new	_	_
15-19	3030-3035	after	_	_	_	_
15-20	3036-3038	it	substance	giv	_	_
15-21	3039-3041	is	_	_	_	_
15-22	3042-3050	released	_	_	_	_
15-23	3051-3055	from	_	_	_	_
15-24	3056-3059	the	substance[174]	new[174]	_	_
15-25	3060-3064	food	substance|substance[174]	giv|new[174]	_	_
15-26	3065-3071	matrix	substance[174]	new[174]	_	_
15-27	3072-3076	into	_	_	_	_
15-28	3077-3080	the	object[175]	giv[175]	_	_
15-29	3081-3097	gastrointestinal	object[175]	giv[175]	_	_
15-30	3098-3103	tract	object[175]	giv[175]	_	_
15-31	3104-3105	.	_	_	_	_

#Text=Several methodologies can be used to assess the bioaccessibility of contaminants or nutrients : 1 ) in vitro , 2 ) ex vivo , 3 ) in situ and 4 ) in vivo models .
16-1	3106-3113	Several	abstract[176]	new[176]	_	_
16-2	3114-3127	methodologies	abstract[176]	new[176]	_	_
16-3	3128-3131	can	_	_	_	_
16-4	3132-3134	be	_	_	_	_
16-5	3135-3139	used	_	_	_	_
16-6	3140-3142	to	_	_	_	_
16-7	3143-3149	assess	_	_	_	_
16-8	3150-3153	the	substance[177]	giv[177]	_	_
16-9	3154-3170	bioaccessibility	substance[177]	giv[177]	_	_
16-10	3171-3173	of	substance[177]	giv[177]	_	_
16-11	3174-3186	contaminants	substance[177]|substance	giv[177]|giv	_	_
16-12	3187-3189	or	substance[177]	giv[177]	_	_
16-13	3190-3199	nutrients	substance[177]|substance[179]	giv[177]|new[179]	_	_
16-14	3200-3201	:	substance[177]|substance[179]	giv[177]|new[179]	_	_
16-15	3202-3203	1	substance[177]|substance[179]	giv[177]|new[179]	_	_
16-16	3204-3205	)	_	_	_	_
16-17	3206-3208	in	_	_	_	_
16-18	3209-3214	vitro	_	_	_	_
16-19	3215-3216	,	_	_	_	_
16-20	3217-3218	2	quantity	new	_	_
16-21	3219-3220	)	_	_	_	_
16-22	3221-3223	ex	_	_	_	_
16-23	3224-3228	vivo	_	_	_	_
16-24	3229-3230	,	_	_	_	_
16-25	3231-3232	3	_	_	_	_
16-26	3233-3234	)	_	_	_	_
16-27	3235-3237	in	_	_	_	_
16-28	3238-3242	situ	_	_	_	_
16-29	3243-3246	and	_	_	_	_
16-30	3247-3248	4	time[181]	new[181]	_	_
16-31	3249-3250	)	time[181]	new[181]	_	_
16-32	3251-3253	in	time[181]	new[181]	_	_
16-33	3254-3258	vivo	time[181]|object|abstract[183]	new[181]|new|new[183]	coref|coref	17-8[186_183]|17-16
16-34	3259-3265	models	time[181]|abstract[183]	new[181]|new[183]	_	_
16-35	3266-3267	.	_	_	_	_

#Text=Among the techniques mentioned before , in vitro models are more commonly used than in vivo models , because of their simplicity , lower cost , lack of ethical issues and good reproducibility under controlled conditions .
17-1	3268-3273	Among	_	_	_	_
17-2	3274-3277	the	abstract[184]	new[184]	_	_
17-3	3278-3288	techniques	abstract[184]	new[184]	_	_
17-4	3289-3298	mentioned	_	_	_	_
17-5	3299-3305	before	_	_	_	_
17-6	3306-3307	,	_	_	_	_
17-7	3308-3310	in	_	_	_	_
17-8	3311-3316	vitro	organization|abstract[186]	new|giv[186]	coref	17-16[188_186]
17-9	3317-3323	models	abstract[186]	giv[186]	_	_
17-10	3324-3327	are	_	_	_	_
17-11	3328-3332	more	_	_	_	_
17-12	3333-3341	commonly	_	_	_	_
17-13	3342-3346	used	_	_	_	_
17-14	3347-3351	than	_	_	_	_
17-15	3352-3354	in	_	_	_	_
17-16	3355-3359	vivo	object|abstract[188]	giv|giv[188]	_	_
17-17	3360-3366	models	abstract[188]	giv[188]	_	_
17-18	3367-3368	,	abstract[188]	giv[188]	_	_
17-19	3369-3376	because	abstract[188]	giv[188]	_	_
17-20	3377-3379	of	abstract[188]	giv[188]	_	_
17-21	3380-3385	their	abstract[188]|abstract[189]	giv[188]|new[189]	_	_
17-22	3386-3396	simplicity	abstract[188]|abstract[189]	giv[188]|new[189]	_	_
17-23	3397-3398	,	abstract[188]	giv[188]	_	_
17-24	3399-3404	lower	abstract[188]|quantity[190]	giv[188]|new[190]	_	_
17-25	3405-3409	cost	abstract[188]|quantity[190]	giv[188]|new[190]	_	_
17-26	3410-3411	,	abstract[188]	giv[188]	_	_
17-27	3412-3416	lack	abstract[188]|abstract[191]	giv[188]|new[191]	_	_
17-28	3417-3419	of	abstract[188]|abstract[191]	giv[188]|new[191]	_	_
17-29	3420-3427	ethical	abstract[188]|abstract[191]|abstract[192]	giv[188]|new[191]|new[192]	_	_
17-30	3428-3434	issues	abstract[188]|abstract[191]|abstract[192]	giv[188]|new[191]|new[192]	_	_
17-31	3435-3438	and	abstract[188]|abstract[191]	giv[188]|new[191]	_	_
17-32	3439-3443	good	abstract[188]|abstract[191]|abstract[193]	giv[188]|new[191]|new[193]	_	_
17-33	3444-3459	reproducibility	abstract[188]|abstract[191]|abstract[193]	giv[188]|new[191]|new[193]	_	_
17-34	3460-3465	under	abstract[188]|abstract[191]|abstract[193]	giv[188]|new[191]|new[193]	_	_
17-35	3466-3476	controlled	abstract[188]|abstract[191]|abstract[193]|abstract[194]	giv[188]|new[191]|new[193]|giv[194]	ana	18-18[0_194]
17-36	3477-3487	conditions	abstract[188]|abstract[191]|abstract[193]|abstract[194]	giv[188]|new[191]|new[193]|giv[194]	_	_
17-37	3488-3489	.	_	_	_	_

#Text=The present work evaluated some acrylamide mitigation strategies , employing a fractional factorial design experiment , and their influence on textural properties and bioaccesibility , by an in vitro simulated digestion assay .
18-1	3490-3493	The	abstract[195]	new[195]	_	_
18-2	3494-3501	present	abstract[195]	new[195]	_	_
18-3	3502-3506	work	abstract[195]	new[195]	_	_
18-4	3507-3516	evaluated	_	_	_	_
18-5	3517-3521	some	abstract[198]	giv[198]	_	_
18-6	3522-3532	acrylamide	substance|abstract[198]	giv|giv[198]	_	_
18-7	3533-3543	mitigation	substance|abstract[198]	giv|giv[198]	_	_
18-8	3544-3554	strategies	abstract[198]	giv[198]	_	_
18-9	3555-3556	,	abstract[198]	giv[198]	_	_
18-10	3557-3566	employing	abstract[198]	giv[198]	_	_
18-11	3567-3568	a	abstract[198]|abstract[201]	giv[198]|new[201]	_	_
18-12	3569-3579	fractional	abstract[198]|abstract[201]	giv[198]|new[201]	_	_
18-13	3580-3589	factorial	abstract[198]|place|abstract[201]	giv[198]|new|new[201]	_	_
18-14	3590-3596	design	abstract[198]|abstract|abstract[201]	giv[198]|new|new[201]	_	_
18-15	3597-3607	experiment	abstract[198]|abstract[201]	giv[198]|new[201]	_	_
18-16	3608-3609	,	abstract[198]	giv[198]	_	_
18-17	3610-3613	and	abstract[198]	giv[198]	_	_
18-18	3614-3619	their	abstract[198]|abstract|abstract[203]	giv[198]|giv|giv[203]	_	_
18-19	3620-3629	influence	abstract[198]|abstract[203]	giv[198]|giv[203]	_	_
18-20	3630-3632	on	abstract[198]|abstract[203]	giv[198]|giv[203]	_	_
18-21	3633-3641	textural	abstract[198]|abstract[203]|abstract[204]	giv[198]|giv[203]|giv[204]	_	_
18-22	3642-3652	properties	abstract[198]|abstract[203]|abstract[204]	giv[198]|giv[203]|giv[204]	_	_
18-23	3653-3656	and	abstract[198]|abstract[203]|abstract[204]	giv[198]|giv[203]|giv[204]	_	_
18-24	3657-3672	bioaccesibility	abstract[198]|abstract[203]|abstract[204]|substance[205]	giv[198]|giv[203]|giv[204]|new[205]	_	_
18-25	3673-3674	,	abstract[198]|abstract[203]|abstract[204]|substance[205]	giv[198]|giv[203]|giv[204]|new[205]	_	_
18-26	3675-3677	by	abstract[198]|abstract[203]|abstract[204]|substance[205]	giv[198]|giv[203]|giv[204]|new[205]	_	_
18-27	3678-3680	an	abstract[198]|abstract[203]|abstract[204]|substance[205]	giv[198]|giv[203]|giv[204]|new[205]	_	_
18-28	3681-3683	in	abstract[198]|abstract[203]|abstract[204]|substance[205]	giv[198]|giv[203]|giv[204]|new[205]	_	_
18-29	3684-3689	vitro	abstract[198]|abstract[203]|abstract[204]|substance[205]	giv[198]|giv[203]|giv[204]|new[205]	_	_
18-30	3690-3699	simulated	abstract[198]|abstract[203]|abstract[204]|substance[205]	giv[198]|giv[203]|giv[204]|new[205]	_	_
18-31	3700-3709	digestion	abstract[198]|abstract[203]|abstract[204]|substance[205]|abstract|abstract[207]	giv[198]|giv[203]|giv[204]|new[205]|giv|new[207]	_	_
18-32	3710-3715	assay	abstract[198]|abstract[203]|abstract[204]|substance[205]|abstract[207]	giv[198]|giv[203]|giv[204]|new[205]|new[207]	_	_
18-33	3716-3717	.	_	_	_	_
